Cargando…

Reciprocal Roles of Angiotensin II and Angiotensin II Receptors Blockade (ARB) in Regulating Cbfa1/RANKL via cAMP Signaling Pathway: Possible Mechanism for Hypertension-Related Osteoporosis and Antagonistic Effect of ARB on Hypertension-Related Osteoporosis

Hypertension is a risk factor for osteoporosis. Animal and epidemiological studies demonstrate that high blood pressure is associated with increased calcium loss, elevated parathyroid hormone, and increased calcium movement from bone. However, the mechanism responsible for hypertension-related osteo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guan, Xiao-Xu, Zhou, Yi, Li, Ji-Yao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Molecular Diversity Preservation International (MDPI) 2011
Materias:	Short Note
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155346/ https://www.ncbi.nlm.nih.gov/pubmed/21845073 http://dx.doi.org/10.3390/ijms12074206

Ejemplares similares

From Angiotensin II to Cyclic Peptides and Angiotensin Receptor Blockers (ARBs): Perspectives of ARBs in COVID-19 Therapy
por: Matsoukas, John, et al.
Publicado: (2021)

Angiotensin receptor blockers (ARBs) in hypertension patients: earlier use of these bettertolerated medications is warranted
por: Aalbers, J
Publicado: (2010)

Angiotensin-converting-enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blocker (ARB) use in COVID-19 prevention or treatment: A paradox
por: Javanmard, Shaghayegh Haghjooy, et al.
Publicado: (2020)

Efficacy of ARB/HCTZ Combination Therapy in Uncontrolled Hypertensive Patients Compared with ARB Monotherapy: A Meta-Analysis
por: Ma, Linlin, et al.
Publicado: (2021)

Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) may be safe for COVID-19 patients
por: Wang, Wenjun, et al.
Publicado: (2021)

Differential Effects in Cardiovascular Markers between High-Dose Angiotensin II Receptor Blocker Monotherapy and Combination Therapy of ARB with Calcium Channel Blocker in Hypertension (DEAR Trial)
por: Kinouchi, Kenichiro, et al.
Publicado: (2011)

Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ
por: Duprez, Daniel, et al.
Publicado: (2011)

Personalized prescription of ACEI/ARBs for hypertensive COVID-19 patients
por: Bertsimas, Dimitris, et al.
Publicado: (2021)

Angiotensin II Receptor Blockers (ARBs Antihypertensive Agents) Increase Replication of SARS-CoV-2 in Vero E6 Cells
por: Pires de Souza, Gabriel Augusto, et al.
Publicado: (2021)

Angiotensin II receptor blockers (ARBs) and manufacturing contamination: A retrospective National Register Study into suspected associated adverse drug reactions
por: Salim, Hamisha, et al.
Publicado: (2022)

Angiotensin receptor blockade and stereotactic body radiation therapy for early stage lung cancer ARB & SBRT for early stage lung cancer
por: Maloney, Lauren T., et al.
Publicado: (2022)

Effects of angiotensin receptor blockers (ARBs) on clinical outcomes of patients with hypertension and COVID-19: A 7-month follow-up cohort study
por: Hadadi, Azar, et al.
Publicado: (2022)

Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension?
por: Huang, Ying, et al.
Publicado: (2020)

Review of evidence on using ACEi and ARBs in patients with hypertension and COVID-19
por: Khan, Sikandar Hayat, et al.
Publicado: (2020)

Antihypertensive treatment with ACEI/ARB of patients with COVID-19 complicated by hypertension
por: Li, Gang, et al.
Publicado: (2020)

ARB might be superior to ACEI for treatment of hypertensive COVID‐19 patients
por: Zhao, Hong‐Jin, et al.
Publicado: (2021)

Renal progenitor cells modulated by angiotensin II receptor blocker (ARB) medication and differentiation towards podocytes in anti-thy1.1 nephritis
por: Wu, Di, et al.
Publicado: (2020)

In silico prediction of ARB resistance: A first step in creating personalized ARB therapy
por: Anderson, Shane D., et al.
Publicado: (2020)

Angiotensin-Converting Enzyme (ACE) Inhibitors and Angiotensin Receptor Blockers (ARB) Are Protective Against ICU Admission and Mortality for Patients With COVID-19 Disease
por: ElAbd, Rawan, et al.
Publicado: (2021)

Cardiovascular and cerebrovascular outcomes in elderly hypertensive patients treated with either ARB or ACEI
por: Ma, Cong, et al.
Publicado: (2012)

Association of ACEi/ARB Use and Clinical Outcomes of COVID-19 Patients With Hypertension
por: Ma, Jing, et al.
Publicado: (2021)

ARB-Based Combination Therapy for the Clinical Management of Hypertension and Hypertension-Related Comorbidities: A Spotlight on Their Use in COVID-19 Patients
por: Presta, Vivianne, et al.
Publicado: (2021)

ACE-inhibitor/angiotensin receptor blockers (ACE-I/ARBs) therapy in COVID-19 infected dialysis patients
por: Daoud, Ahmed, et al.
Publicado: (2021)

From ARB to ARNI in Cardiovascular Control
por: Uijl, Estrellita, et al.
Publicado: (2016)

Repurposing ARBs as treatments for breast cancer
por: George, Amee J., et al.
Publicado: (2017)

The histological spectrum of ARB‐induced gastritis
por: Storozuk, Tanner, et al.
Publicado: (2022)

Need to Revisit Step Therapy for ARBs
por: Ram, C. Venkata, et al.
Publicado: (2007)

Utilization of angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) in patients diagnosed with diabetes: Analysis from the National Ambulatory Medical Care Survey
por: Ibrahim, Sarai L., et al.
Publicado: (2016)

RENAL HYPERTENSION IN RATS IMMUNIZED AGAINST ANGIOTENSIN I AND ANGIOTENSIN II
por: Oates, Helen F., et al.
Publicado: (1974)

Effect of angiotensin II blockade on central blood pressure and arterial stiffness in subjects with hypertension
por: Safar, Michel E
Publicado: (2010)

COVID-19-related deaths not increased with ACE inhibitor or ARB use
Publicado: (2020)

Antihypertensive Therapy by ACEI/ARB Is Associated With Intestinal Flora Alterations and Metabolomic Profiles in Hypertensive Patients
por: Dong, Ying, et al.
Publicado: (2022)

Group-Based Trajectory Modeling to Identify Patterns of Adherence and Its Predictors Among Older Adults on Angiotensin-Converting Enzyme Inhibitors (ACEIs)/Angiotensin Receptor Blockers (ARBs)
por: Paranjpe, Rutugandha, et al.
Publicado: (2020)

MON-596 Effects of Angiotensin Type 1 Receptor Blockers (ARBs) on the Expression and Secretion of Adiponectin and Leptin in Human White Adipocytes
por: Hattori, Naoki, et al.
Publicado: (2020)

Centrally acting ACE inhibitor (cACEi) and angiotensin receptor blocker (cARB) use and cognitive dysfunction in patients with SLE
por: Dobrowolski, Chrisanna, et al.
Publicado: (2023)

User of angiotensin-converting-enzyme inhibitor and/or angiotensin II receptor blocker might be associated with vascular calcification in predialysis chronic kidney disease patients: a retrospective single-center observational study: ACEI/ARB and vascular calcification
por: Takaori, Kaori, et al.
Publicado: (2021)

Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin-Receptor Blockers (ARBs) in Patients at High Risk of Cardiovascular Events: A Meta-Analysis of 10 Randomised Placebo-Controlled Trials
por: Ong, Hean Teik, et al.
Publicado: (2013)

Effects of ACEIs Versus ARBs on Proteinuria or Albuminuria in Primary Hypertension: A Meta-Analysis of Randomized Trials
por: Xu, Rui, et al.
Publicado: (2015)

Comparison of Effects of ACEIs and ARBs on Albuminuria and Hyperkalemia in Indonesian Hypertensive Type 2 Diabetes Mellitus Patients
por: Agustina, Putri S., et al.
Publicado: (2020)

Effects of ACEI/ARB or CCB use on atrial fibrillation in hypertensive patients following permanent pacemaker implantation
por: Liu, Zhijie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_anmleoqtsjkec4s9d3emeug6ro